NEOVACS SA Share Price Deutsche Boerse AG
Equities
0LW
FR001400HDX0
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0005 EUR | -.--% |
|
-.--% | -.--% |
06-17 | Neovacs: collaboration agreement with CNRS | CF |
06-10 | Neovacs: presents results from vaccine candidates | CF |
Sales 2022 | 1.11K 1.19K 94.27K | Sales 2023 | 533K 571K 45.22M | Capitalization | 278 297.77 23.57K |
---|---|---|---|---|---|
Net income 2022 | -3M -3.21M -254M | Net income 2023 | -8M -8.57M -678M | EV / Sales 2022 | - |
Net cash position 2022 | 5.55M 5.95M 471M | Net cash position 2023 | 237K 253K 20.05M | EV / Sales 2023 | -0.44 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
-0.08
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0.12% |
3 months | -99.04% |
![Extreme 0.00050000](/images/extremecours_fleche.png)
![Extreme 0.00050000](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Hugo Brugière
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | - | 30/09/20 | |
Vincent Serra
COO | Chief Operating Officer | 55 | 19/02/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 85 | 27/05/03 | |
Daniel Zagury
FOU | Founder | - | 15/04/93 |
Hugo Brugière
CEO | Chief Executive Officer | - | - |
1st Jan change | Capi. | |
---|---|---|
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
+10.74% | 25.92B | |
-13.50% | 26.03B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B | |
-12.61% | 10.64B |
- Stock Market
- Equities
- ALNEV Stock
- 0LW Stock